NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

特發性肺纖維化:全球臨床試驗檢討(2020年下半年)

Idiopathic Pulmonary Fibrosis Disease - Global Clinical Trials Review, H2, 2020

出版商 GlobalData 商品編碼 980172
出版日期 內容資訊 英文 311 Pages
訂單完成後即時交付
價格
特發性肺纖維化:全球臨床試驗檢討(2020年下半年) Idiopathic Pulmonary Fibrosis Disease - Global Clinical Trials Review, H2, 2020
出版日期: 2020年12月22日內容資訊: 英文 311 Pages
簡介

本報告提供突發性肺纖維化的相關調查,提供世界主要國家中進行的實驗數及其平均登記數概要,刊載各地區·階段·臨床試驗現狀·端點現狀·贊助商類型的臨床試驗,進行臨床試驗中的藥物,過去5年的登記趨勢等資料。

目錄

目錄

表格清單

圖清單

  • 報告指南
  • 臨床試驗調查範圍
  • 各地區的臨床試驗
  • 各國臨床試驗與平均登記
  • 亞太地區中對臨床試驗有貢獻的主要5個國家
  • 歐洲中對臨床試驗有貢獻的主要5個國家
  • 北美中對臨床試驗有貢獻的主要國家
  • 中東和非洲中對臨床試驗有貢獻的主要5個國家
  • 中南美中對臨床試驗有貢獻的主要5個國家
  • G7各國:呼吸系統臨床試驗上突發性肺纖維化的比例
  • 不同階段:G7各國的臨床試驗
  • 各臨床試驗狀態:G7各國的臨床試驗
  • E7各國:呼吸系統臨床試驗上突發性肺纖維化的比例
  • 不同階段:E7各國的臨床試驗
  • 各臨床試驗狀態:E7各國的臨床試驗
  • 不同階段的臨床試驗
  • 不同階段的進行中的臨床試驗
  • 各臨床試驗狀態的臨床試驗
  • 各端點狀態的臨床試驗
  • 特定連續期間內所募集的實驗對象
  • 各贊助商類型的臨床試驗
  • 主要贊助商
  • 參加治療藥物臨床實驗的主要企業
  • 主要藥物
  • 臨床試驗簡介的概述

附錄

  • 簡稱
  • 定義
  • 調查手法
  • 2次調查
  • 關於GlobalData
  • 諮詢方式
  • 資訊來源

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC6571CTIDB

GlobalData's clinical trial report, "Idiopathic Pulmonary Fibrosis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Idiopathic Pulmonary Fibrosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic Pulmonary Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Source

List of Tables

List of Tables

  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Region, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2020*
  • Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*

List of Figures

List of Figures

  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2020*
  • Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • GlobalData Methodology